It has been reported in the literature that PTBP1 can be used as a biomarker for poor prognosis in bladder cancer (Bielli et al., 2018), and PTBP3 as a therapeutic target for gastric cancer (Liang et al., 2017). Here, PTBP3 is linked to urinary bladder carcinoma.